An observational study in Hip Arthritis, Hip Disease and Hip Fractures, sponsored by Zimmer Biomet. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Zimmer Biomet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hip Fractures by Zimmer Biomet — 5 open to participants now, 8 under way, none of them phase 3. Hip Fractures · Zimmer Biomet.
Among the 16 studies in Hip Fractures by Zimmer Biomet, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2020, is one of 11 observational ones, and was the 6th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →5 of the 16 studies in Hip Fractures by Zimmer Biomet are open now, in 4 countries. Recruiting first, the newest first:
Zimmer Biomet · Sites in United States
Ages 18+
Zimmer Biomet · Sites in United States
Ages 18+
Zimmer Biomet · Sites in United States
Ages 18–80
Zimmer Biomet · Sites in United States, Belgium, Italy and 1 more country
Ages 18–80
By country, each count listing its studies:
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2020.
This study's planned enrollment of 820 is above the median of 149 across 280 observational studies indexed under Hip Fractures.
Median enrollment 240 across the 5 interventional studies, 149 across the 11 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.
1 of the studies in Hip Fractures by Zimmer Biomet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05199870Zimmer BiometMDR - PMCF Study for RingLoc Bipolar Acetabular Cup and Endo II Femoral Heads | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Hip Fractures by Zimmer Biomet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up*. Since Taperloc Complete was introduced to the EU in 2010, all available retrospective data will be collected from each patient and a prospective aspect to the study will be necessary to reach the 10-year time point.
The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up*. Since Taperloc Complete was introduced to the EU in 2010, all available retrospective data will be collected from each patient and a prospective aspect to the study will be necessary to reach the 10-year time point.
The primary objective is to confirm safety of the study products. This will be assessed by recording the incidence and frequency of revisions, complications, and adverse events. Relationship of the events to either implant or instrumentation should be specified.
The secondary objective is the assessment of performance and clinical benefits by analyzing recorded patient-reported clinical outcomes measures (PROMs).
*The most recent available data will be used. If any of the listed time points are not available, data will be used from last available time point and follow-up will move forward at the closest available time point
A consecutive series of patients implanted with the Taperloc Complete Stems in primary or revision total hip arthroplasty according to the approved indications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients that have been implanted with a Taperloc Complete Stem to repair hip malfunction/disease.
Device: Taperloc Complete Stem
Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
Device Safety assessed through the frequency and incidence of revisions, complications and Adverse Events.
The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications and adverse events. Relation of the events to either implant or instrumentation should be specified.
Time frame: Out to 10 Years
Device Performance and Benefits evaluated through the Harris Hip Score
The HHS is divided into 4 sub-categories; pain (44 points), function (47 points), range of motion (5 points), and absence of deformity (4 points). Patients select a discrete set of answers which correspond to predefined point allocations based on the category. To obtain a final score, these values are summed.
Time frame: Out to 10 Years
Device Performance and Benefits evaluated through the Oxford Hip Score
The OHS is a patient-completed, 12-question evaluation. Each item is scored from 1 to 5, with 1 representing best outcome/least symptoms and 5 representing worst outcome/most symptoms.
Time frame: Out to 10 Years
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Feb 2032, 143 months after the start.
Of 124 observational studies under Hip Fractures, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 83. This study's planned 143 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.